Insmed begins Japanese sales of BRINSUPRI for non-cystic fibrosis bronchiectasis
Insmed said on October 19, 2026 that BRINSUPRI Tablets 25 mg had entered commercial distribution in Japan for non-cystic fibrosis bronchiectasis. Japan's health ministry granted approval in August 2026, relying on Phase 3 ASPEN results, and the once-daily oral drug is authorized for adults and children aged 12 years and older. Insmed describes BRINSUPRI as Japan's first and only approved treatment specifically available for this condition.
Why it matters
The launch gives Insmed access to Japanese prescriptions for an indication with no previously approved therapy there, creating a new commercial market for BRINSUPRI. The treatment carries reported risks including skin and gum-related adverse reactions, which may affect prescribing and monitoring.
Key facts
- 1Insmed launched BRINSUPRI Tablets 25 mg in Japan on October 19, 2026. prnewswire.com
- 2Japanese approval covers adults and pediatric patients 12 years and older with non-cystic fibrosis bronchiectasis. prnewswire.com
- 3The Japan Ministry of Health, Labour, and Welfare approved BRINSUPRI in August 2026 based on Phase 3 ASPEN study results. prnewswire.com
- 4The ASPEN trial's most common adverse reactions at a rate of ≥2% included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. prnewswire.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.